Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

ID Care Physicians Preach Hope and Excitement After Receiving First Doses of COVID-19 Vaccine
  • USA - English

ID Care, the largest network of infectious disease specialists on the East Coast, is taking part in the first round of COVID-19 vaccines, marking a huge moment for the state of New Jersey.


News provided by

ID Care

Jan 08, 2021, 08:30 ET

Share this article

Share toX

Share this article

Share toX


HILLSBOROUGH, N.J., Jan. 8, 2021 /PRNewswire-PRWeb/ -- After awaiting the highly anticipated emergency use authorization (EUA) by the Food and Drug Administration (FDA), two different COVID-19 vaccines have arrived in the United States, bringing renewed hope to millions of people across the country. In the state of New Jersey, healthcare professionals have started to receive their first doses of the Pfizer and Moderna vaccines, including the physicians and medical personnel at ID Care, the East Coast's largest network of infectious diseases specialists and a partner to many healthcare organizations across New Jersey.

Over the course of the pandemic, ID Care has been responsible for treating over 25% of the hospitalized COVID-19 patients in the state. As frontline healthcare workers with direct contact with over 8,000 patients, the arrival of the vaccines marks a huge moment in finally gaining an upper hand on the disease. Upon receiving the first dose of the Pfizer vaccine, Dr. Nazar C. Raoof of ID Care said, "After seeing the first case of COVID-19 in our area, this is an emotional moment for me."

The data is convincing, the immediate safety data is clear. Dr. Ronald Nahass, President and Co-Founder ID Care

Post this

A rollout of the Pfizer and Moderna vaccines has been ongoing for the past two weeks with healthcare personnel receiving the first doses, followed by non-healthcare essential workers, adults with high-risk medical conditions, and finally adults over the age of 65. The general public will most likely have to wait several more months before receiving a vaccine, but once they do, they can expect a positive experience. "Most vaccines are 2 doses, 3 to 4 weeks apart, and protection will occur 1 to 2 weeks after the second dose," said Dr. Nahass, President and Co-Founder of ID Care. "Humoral immune responses at this point have been recognized for up to 6 months or longer, which is good news. We would like it to be longer, but not enough time has passed to know exactly how long it will last. However, we do know that the antibody responses with similar viruses such as SARS CoV1 and MERS may be present for up to three years."

ID Care continues to be on the front lines of the COVID-19 effort and encourages healthcare workers to understand the value of immunizations and communicate the benefits to patients. "In the United States, over 300,000 people have died," said Dr. Nahass. "In order to stop the spread of COVID-19, we need to reach about 70-80% immunity as a population. At the moment, it's estimated about 10% to 15% of the population has been infected, and in order to reach the herd immunity threshold of 60%, that means the infection rate would need to be five times as high. So, if you do the math, in order to get to that 75% immunity naturally, we would see about 1.2 million deaths. So that's the power of a vaccine. It will help get us to that 80% number without incurring all the deaths."

The ID Care team notes that the vaccines are safe and effective with now over 5,000,000 individuals in the US having received the vaccines over the past four month with no signs of life-threatening toxicity and side effects. In addition, the ability to develop the vaccines on such a short timeline is an effort that should be applauded, not feared. The clinical research team at ID Care has over 30 years of experience in the research and development of numerous vaccines and can assure the public that the FDA has used the same strict standards in reviewing the COVID-19 vaccines that it has used on other vaccines for decades. Despite the rapid development, no steps have been skipped. In fact, two independent advisory committees have reviewed the results – The Vaccine and Related Biological Products Advisory Committee (VRBPCA) that advises the FDA, and The Advisory Committee on Immunization Practices (ACIP) that advises the CDC– and both committees have deemed the vaccines are safe and effective. In relaying this information to the general public, Dr. Nahass has words of encouragement for healthcare organizations: "The data is convincing, the immediate safety data is clear. The new technology and the method of development have really provided a lot of comfort for me, and it should do the same for patients."

While the pandemic is far from over, the majority of healthcare workers at ID Care have already received a COVID-19 vaccine and described the moment as a monumental achievement. "I feel privileged, excited, and relieved. It is a very proud moment," said ID Care physician, Dr. Rebecca A. Marsh. "I feel like it's a bright light of hope in the middle of a very dark winter."

About ID Care
ID Care is New Jersey's largest network of board-certified infectious disease specialists – seeing over 200,000 patients a year and practicing in nine convenient locations and over 130 care facilities throughout the state (including hospitals, rehab facilities and sub-acute facilities). As clinical leaders, innovators, and researchers, ID Care provides patients with personalized solutions for a comprehensive range of illnesses and infections. Specializing in every aspect of infectious diseases — including HIV, hepatitis, pneumonia, tick-borne diseases, wound infections, travel-related illnesses, and others — ID Care physicians offer the most effective prevention methods, accurate diagnoses, and state-of-the-art treatments available today. For more information on ID Care, visit http://www.IDCare.com or contact James Padley, Chief Operating Officer, ID Care. He can be reached at 908-281-0221 ext. 107, or via email at [email protected].

Media Contact

James Padley, ID Care, +1 908-281-0221, [email protected]

SOURCE ID Care

Related Links

http://www.IDCare.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.